Buscador Simpla

Home | Sala de prensa | Trabajos Benznidazol

Abarax - Benznidazol

Descargar PDF (1261 kb)


Octubre 2012

Normas para el Diagnóstico de la Infección por Trypanosoma cruzi

Ministerio de Salud de la Nación
La ley 22360 sancionada en 1980 declara de interés nacional la prevención y lucha contra la enfermedad de Chagas, asignándole carácter prioritario dentro de la política sanitaria nacional. En cumplimiento de esta ley el entonces Ministerio de Salud Pública y Medio Ambiente dicta la Resolución Nº 4 del 6 de enero de 1983, donde faculta al ex Instituto Nacional de Diagnóstico e Investigación de la enfermedad de Chagas, Dr. Mario Fatala Chabén a establecer las normas técnicas para realizar el diagnóstico de la infección producida por el Trypanosoma cruzi, agente causal de la enfermedad... »

Descargar PDF (1542 kb)


Agosto 2012

(Enfermedad de Chagas)

Ministerio de Salud de la Nación
En el marco de las actividades de control no vectorial de la Enfermedad de Chagas, se han elaborado las “Guías para la Atención del Paciente Infectado por Trypanosoma cruzi”, aprobadas por resolución ministerial Nº 1870 en noviembre de 2006. El presente documento actualiza y reemplaza dichas Guías... »

Descargar PDF (383 kb)


Julio 2012

Chagasic cardiomyopathy, from acute to chronic: is this mediated by host susceptibility factors?

Chronic chagasic cardiomyopathy (CCC) is the main contributor to morbidity and mortality among individuals chronically infected with the protozoan parasite Trypanosoma cruzi. However, cardiomyopathy develops in fewer than one-third of these patients. Among the different mechanisms to explain this variability are environmental factors, T. cruzi genetic diversity, and host susceptibility. CCC is the culmination of a pathologic process with an onset during the acute infection phase. Previous studies of host genetic factors have been limited to a few candidate genes. This review describes the pathologic features of acute and chronic myocarditis and the host susceptibility factors that may contribute to the development of chagasic cardiomyopathy... »

Descargar PDF (175 kb)


13 de Febrero de 2012

Safety of benznidazole use in the treatment of chronic Chagas’ disease

Alejandro M. Hasslocher-Moreno, Pedro E. A. A. do Brasil, Andrea S. de Sousa, Sergio S. Xavier, Mayara C. Chambela and Gilberto M. Sperandio da Silva*
Chagas’ disease is caused by Trypanosoma cruzi. In 1993, the World Bank considered Chagas’ disease to be the parasitic disease with the greatest socio-economic impact in South America.1 There are an estimated 7.5 million people infected in Latin America... »

Descargar PDF (746 kb)



American Trypanosomiasis (Chagas Disease)

Anis Rassi Jr, MD, PhDa,*, Anis Rassi, MDa, Joffre Marcondes de Rezende, MDb... »

Descargar PDF (309 kb)

Special Article


Screening and Treatment of Chagas Disease in Organ Transplant Recipients in the United States: Recommendations from the Chagas in Transplant Working Group

Donor-derived transmission of Trypanosoma cruzi, the etiologic agent of Chagas disease, has emerged as an issue in the United States over the past 10 years. Acute T. cruzi infection causes substantial morbidity and mortality in the posttransplant setting if not recognized and treated early. We assembled a working group of transplant infectious disease specialists... »

Descargar PDF (10 kb)


20-21 de Octubre de 201


2do Encuentro Nacional de Enfermedades Olvidadas XIV Simposio Internacional sobre el Control de Enfermedades Transmitidas por Vectores... »

Descargar PDF (100 kb)


12 de Octubre de 2011

First Century of Chagas’ Disease: An Overview on Novel Approaches to Nifurtimox and Benznidazole Delivery Systems

CLAUDIO J. SALOMON - Area Tecnica Farmac ´ eutica, Departamento Farmacia, Facultad de Ciencias Bioqu ´ ´ımicas y Farmaceuticas, Suipacha 531, 2000. ´ Universidad Nacional de Rosario, IQUIR-CONICET, Rosario, Argentina... »

Descargar PDF (368 kb)



Population Pharmacokinetics of Benznidazole in Children with Chagas’ Disease

There is an unmet medical need for new paediatric formulations for Chagas’ disease (CD). Also, there is an absolute lack of information on benznidazole (BZ) pharmacokinetic (PK) data for paediatric population and its relationship with treatment safety and efficacy... »

Descargar PDF (618 kb)



Chagas Disease: Coming to a Place Near You

Eva Rawlings Parker, Aisha Sethi Chagas disease, or American trypanosomiasis, is a parasitic infection caused by the flagellate protozoan Trypanosoma cruzi, an organism that is endemic to Latin America. This disease was first described in 1909 by the Brazilian physician Carlos Chagas, and today the World Health Organization (WHO) estimates that approximately 10 million people are infected.1 Although not formally identified until 100 years ago, more recent paleoparasitology studies have revealed the presence of T cruzi DNA in tissue from 9000-year-old pre-Colombian mummies, providing a historical glimpse into an illness that has likely plagued humans for thousands of years and continues to have significant morbidity and mortality and impose far-reaching socioeconomic effects... »

Descargar PDF (205 kb)



Chagas disease: changes in knowledge and management

François-Xavier Lescure, Guillaume Le Loup, Hector Freilij, Michel Develoux, Luc Paris, Laurent Brutus, Gilles Pialoux
More than 100 years after the discovery of human American trypanosomiasis by Carlos Chagas, our knowledge and management of the disease are profoundly changing. Substantial progress made by disease control programmes in most endemic areas contrasts with persisting diffi culties in the Gran Chaco region in South America and the recent emergence of the disease in non-endemic areas because of population movements. In terms of pathogenesis, major discoveries have been made about the life cycle and genomics of Trypanosoma cruzi, and the role of the parasite itself in the chronic phase of the disease... »

Descargar PDF (501 kb)



The BENEFIT trial: testing the hypothesis that trypanocidal therapy is beneficial for patients with chronic Chagas heart disease

J Antonio Marin-Neto , Anis Rassi Jr , Alvaro Avezum Jr , Antonio C Mattos , Anis Rassi
Among the pathophysiological derangements operating in the chronic phase of Chagas disease, parasite persistence is likely to constitute the main mechanism of myocardial injury in patients with chronic chagasic cardiomyopathy... »

Descargar PDF (317 kb)



Chagasic encephalitis in HIV patients: common presentation of an evolving epidemiological and clinical association

Carlos A DiazGranados, Carlos H Saavedra-Trujillo, Monica Mantilla, Sandra L Valderrama, Carlos Alquichire, Carlos Franco-Paredes
We present a case of chagasic meningoencephalitis reactivation in an HIV-infected woman with advanced immunosuppression. Prolonged survival was attained with antiparasitic therapy and secondary prophylaxis, in conjunction with the use of highly-active antiretroviral therapy... »

Descargar PDF (1134 kb)



Therapy, diagnosis and prognosis of chronic Chagas disease: insight gained in Argentina

Sergio Sosa-Estani, Rodolfo Viotti, Elsa Leonor Segura
The purpose of this review is to describe research findings regarding chronic Chagas disease in Argentina that have changed the standards of care for patients with Trypanosoma cruzi infection... »

Descargar PDF (142 kb)



Rationale and design of a randomized placebo-controlled trial assessing the effects of etiologic treatment in Chagas' cardiomyopathy: The BENznidazole Evaluation For Interrupting Trypanosomiasis (BENEFIT)

Jose Antonio Marin-Neto, Anis Rassi, Carlos A. Morillo, Alvaro Avezum, Stuart J. Connolly, Sergio Sosa-Estani, Fernando Rosas, and Salim Yusuf, on behalf of BENEFIT Investigators Sao Paulo and Goiania, Brazil; Hamilton, Ontario, Canada; Buenos Aires, Argentina; Bogota, Colombia... »